Computational Prediction of Angiotensin Receptor Blocker Affinity to
Polymorphic Angiotensin Type 1 Receptor for Personalized Therapy
1/3
ABOUT
OF THE USA HAS HYPERTENSION
103
A TOTAL OF
POLYMORPHISMS IN THE BINDING POCKET OF THE AT1R WERE STUDIED
200
SOME ARBS ARE AMONG THE TOP
DRUGS ADMINISTERED IN THE USA
INTRODUCTION
When patients are diagnosed with hypertension, they are often prescribed one of eight ARBs- Angiotensin Receptor Blockers.
At the molecular level, cardiovascular diseases may be caused by a surplus of Angiotensin II binding to the Angiotensin Type 1 Recptor (AT1R), as Angiotensin II vasoconstricts blood vessels. ARBs are a popular and effective therapy because they block Angiotensin II from binding to the AT1R, and relieve the over-constriction of blood vessels.
But what happens when a patient has a polymorphism, a common mutation, which changes the structure of their AT1 Receptor?
Will it render the drug ineffective?
If so, is there a solution?
ASNA TABASSUM
As a junior at Ruben S. Ayala High School in Southern California, I have been incredibly enamored with the sciences- particularly biology and physics. In college, I hope to explore the intersection of science and policy.
Yet, when I'm not studying, I love public speaking, researching, and volunteering at my local hospital. My favorite novels include The Kite Runner and Wonder, but reading articles on Quora satiate my everyday curiosities.
In the future, I plan to practice medicine abroad in underserved countries as well as conduct research. I am particularly interested in humantarian leadership as well as the cardiovascular field.
Thank you for taking the time to read about my research efforts. I welcome any and all feedback- head to the Discussion page, and I will answer as soon as possible!